Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes

Clinical and Experimental Ophthalmology

Volumn 40, Issue 1, 2012, Pages 67-72

  Troutbeck, Robyn ^a   Bunting, Roland ^a   van Heerdon, Anton ^a   Cain, Melinda ^a   Guymer, Robyn ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Choroidal neovascular membrane; Multifocal choroiditis; Myopia; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CHOROIDITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA THICKNESS; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; CHOROIDITIS; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; MYOPIA; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84856651531     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02719.x     Document Type: Article

References (23)

1. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496-503.
2. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986; 93: 1169-76.
3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-2.
4. Spaide RF. Choroidal neovascularization in younger patients. Curr Opin Ophthalmol 1999; 10: 177-81.
5. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107: 1593-600.
6. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-14.
7. Hawkins BS, Bressler NM, Bressler SB etal. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: Submacular Surgery Trials (SST) Group H Trial: SST Report No. 9. Arch Ophthalmol 2004; 122: 1597-611.
8. Lee YA, Ho TC, Chen MS, Yang CH, Yang CM. Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization. Eye 2009; 23: 645-51.
9. Ruiz-Oliva F, Cortes J. Verteporfin in Photodynamic Therapy (VIP) Study group. Ophthalmology. 2002; 109: 1043; author reply 1043; author reply 1044.
10. Rosenfeld PJ, Brown DM, Heier JS etal. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
11. Brown DM, Kaiser PK, Michels M etal. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
12. Regillo CD, Brown DM, Abraham P etal. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008; 145: 239-48.
13. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JMJ, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol 2008; 126: 941-5.
14. Gupta B, Elagouz M, Sivaprasad S. Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration. Eye 2010; 24: 203-13.
15. Heier JS, Brown D, Ciulla T etal. Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. Ophthalmology 2011; 118: 111-8.
16. Sawa M, Gomi F, Tsujikawa M, Sakaguchi H, Tano Y. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks. Am J Ophthalmol 2009; 148: 584-590.e2.
17. Mansour AM, Mackensen F, Arevalo JF etal. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008; 146: 410-16.
18. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009; 93: 448-51.
19. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2010; ISBN 3-900051-07-0. Accessed January 2011. Available from:
20. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
21. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 923-6.
22. Tabandeh H, Flynn HWJ, Scott IU etal. Visual acuity outcomes of patients 50years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106: 2063-7.
23. Blinder KJ, Blumenkranz MS, Bressler NM etal. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP report no. 3. Ophthalmology 2003; 110: 667-73.